CD19 and B-cell chronic lymphocytic leukemia: In a promising phase 1/2 trial (NCT03056339), researchers developed allogeneic CD19 CAR-NK cells derived from cord blood to treat patients with relapsed or refractory non-Hodgkin’s lymphoma or chronic lymphocytic leukemia (CLL).